SCHEMBL4077565

SCHEMBL4077565

Nc1cccc2ccc(F)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
HPGD P15428 3/20 0.54
CYP3A4 P08684 3/20 0.54
TSHR P16473 2/20 0.54
HSD17B10 Q99714 2/20 0.54
KEAP1 Q14145 1/20 0.54
F2 P00734 1/20 0.53
PLG P00747 1/20 0.53
PLAU P00749 1/20 0.53
PLAT P00750 1/20 0.53
KLK1 P06870 1/20 0.53
PRSS1 P07477 1/20 0.53
MAPT P10636 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
KDM4E B2RXH2 2/20 0.50
POLB P06746 2/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
TDP2 O95551 1/20 0.50
CASP6 P55212 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7416083 0.98 ALDH1A1 (0.52) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL30369928 0.83 ALDH1A1 (0.54) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL4084096 0.83 ALDH1A1 (0.54) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL1458869 0.77 CYP2A6 (0.52) ALDH1A1TSHRHSD17B10MAPTTDP1
SCHEMBL729842 0.77 CTDSP1 (0.63) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL29405526 0.77 CTDSP1 (0.63) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL29498396 0.77 CTDSP1 (0.63) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL29351158 0.76 ALDH1A1 (0.62) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL5545202 0.76 ALDH1A1 (0.62) ALDH1A1HPGDCYP3A4TSHRHSD17B10
SCHEMBL30377849 0.75 CYP1A2 (0.52) ALDH1A1HSD17B10TDP1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 US disclosed
EP-4647424-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-11-12 EP disclosed
WO-2024181437-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY 中外製薬株式会社 2024-09-06 WO disclosed
US-10793584-B2 Naphthobischalcogenadiazole derivative and production method therefor OSAKA UNIVERSITY (JP) 2020-10-06 US disclosed
US-20190337966-A1 NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR OSAKA UNIVERSITY (JP) 2019-11-07 US disclosed
CN-106536480-B Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors 艾特奥斯治疗公司 2019-09-03 CN disclosed
US-10398679-B2 Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors ITEOS THERAPEUTICS (BE) 2019-09-03 US disclosed
US-10398679-B2 Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors ITEOS THERAPEUTICS (BE) 2019-09-03 US disclosed
US-20180214415-A1 TREATMENT METHOD UTILIZING PYRROLIDINE-2, 5-DIONE DERIVATIVES AS IDO1 INHIBITORS ITEOS THERAPEUTICS (BE) 2018-08-02 US disclosed
US-20180214415-A1 TREATMENT METHOD UTILIZING PYRROLIDINE-2, 5-DIONE DERIVATIVES AS IDO1 INHIBITORS ITEOS THERAPEUTICS (BE) 2018-08-02 US disclosed
US-20170035731-A1 PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS ITEOS THERAPEUTICS (BE) 2017-02-09 US disclosed
US-20170035731-A1 PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS ITEOS THERAPEUTICS (BE) 2017-02-09 US disclosed
US-20150329525-A1 PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS ITEOS THERAPEUTICS (BE) 2015-11-19 US disclosed
WO-2015173764-A1 PYRROLIDINE-2,5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS ITEOS THERAPEUTICS (BE) 2015-11-19 WO disclosed
CN-1863784-B 2-naphthylimino-1,3-thiazine derivative SHIONOGI & CO 2010-11-17 CN disclosed
US-7482339-B2 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2009-01-27 US disclosed
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2006-12-14 US disclosed
CN-1863784-A 2-naphthylimino-1,3-thiazine derivative SHIONOGI & CO (JP) 2006-11-15 CN disclosed
EP-1659117-A1 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2006-05-24 EP disclosed
US-4950670-A Psychological and cardiovascular disorders SYNTHELABO (FR) 1990-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10793584-B2 Naphthobischalcogenadiazole derivative and production method therefor CYP24A1, CYP26B1, CYP21A2 ALDH1A1 600/4885HPGD 815/4885CYP3A4 389/4885
US-20190337966-A1 NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR CYP24A1, CYP26B1, CYP21A2 ALDH1A1 600/4885HPGD 815/4885CYP3A4 389/4885
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY MYT1, NTMT1, MYL6 ALDH1A1 2880/4885HPGD 2650/4885CYP3A4 1957/4885
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative NPM1, OXTR, CYP2S1 ALDH1A1 1571/4885HPGD 580/4885CYP3A4 95/4885
US-20170035731-A1 PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS IDO1, IDO2, ARG1 ALDH1A1 357/4885HPGD 44/4885CYP3A4 905/4885
US-20150329525-A1 PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS IDO1, IDO2, ARG1 ALDH1A1 212/4885HPGD 47/4885CYP3A4 437/4885
US-20180214415-A1 TREATMENT METHOD UTILIZING PYRROLIDINE-2, 5-DIONE DERIVATIVES AS IDO1 INHIBITORS IDO1, IDO2, NAT1 ALDH1A1 241/4885HPGD 67/4885CYP3A4 910/4885
US-10398679-B2 Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors IDO1, IDO2, NAT1 ALDH1A1 241/4885HPGD 67/4885CYP3A4 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.